Aimmune Therapeutics Completes and Exceeds North American Enrollment Target Ahead of Schedule in Phase 3 PALISADE Trial of AR101 for the Treatment of Peanut Allergy; Company Accelerates Plans for Real-World Experience Study in the U.S. by mparnell | Sep 20, 2016 | Portfolio News
Rapid Micro Biosystems Announces New Chief Business Officer / Chief Financial Officer by mparnell | Sep 19, 2016 | Portfolio News
Venus Concept Unveils Venus Freeze Plus™, the Easiest-to-Use System for Non-Invasive Anti-Aging Treatments by mparnell | Sep 16, 2016 | Portfolio News
Aptinyx Receives FDA Fast Track Designation for Development of NYX-2925 as Treatment for Neuropathic Pain Associated with Diabetic Peripheral Neuropathy by mparnell | Sep 13, 2016 | Portfolio News